News List
FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma
2021-09-08
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S.
Novartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis
2021-08-23
August 17, 2021 – Novartis today announced that the China National Medical Products Administration (
Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU
2021-07-27
Berlin, Germany, July 21, 2021– The European Commission has granted marketing authorization in the E
USFDA approves KIT inhibitor Ayvakit (Avatinib)
2021-06-25
CStone's partner Blueprint Medicines recently announced that the U.S. Food and Drug Administrati
AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
2021-06-01
Late-breaking data analyses presented by AbbVie (NYSE: ABBV) at Digestive Disease Week®(DDW) Virtual
Xofluza was approved in China
2021-05-13
On April 29, 2021, Roche China announced that its innovative influenza drug Xofluza® (Mabaloxavir) h
Tagrisso approved in China in early lung cancer
2021-04-16
AstraZeneca'sTagrisso(osimertinib) has been approved in China for the adjuvant treatment of pati
Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI
2021-03-15
Gilead Sciences, Inc. (Nasdaq: GILD) today presented additional results from the Phase 2/3 CAPELLA t
BeiGene Announces EMA Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with WM
2021-02-25
On June 18, 2020, BeiGene, Ltd. (“BeiGene” or the “Company”), a commercial-stage biotechnology compa
VISEN Pharmaceutical's TransCon C-type natriuretic peptide Phase II clinical trial application approved in China
2021-02-09
January 7, VISEN Pharmaceuticals announced that it had submitted TransCon CNP (TransCon C-type natri